• NIHPA Author Manuscripts >
• PMC3630076

Am J Clin Exp Immunol. Author manuscript; available in PMC 2013 April 18.

Published in final edited form as:

Am J Clin Exp Immunol. 2012 June 30; 1(1): 20–27.

Published online 2012 April 23.

PMCID: PMC3630076

NIHMSID: NIHMS459240

Interleukin 13 and the evolution of asthma therapy

Gabriele Grünig,¹ David B. Corry,² Joan Reibman,³ and Marsha Wills-Karp⁴

Author information ► Copyright and License information ►

Summary

This is a concise review on Interleukin (IL)-13 and the evolution of asthma therapy, from discovery of the molecule, the identification of its pathogenic role in animal models of asthma, to the development of clinically successful neutralizing agents. The translational path from basic research to clinical application was not sequential as expected but random with respect to the tools (molecular & cell biology, animal models, human studies) used and to the application of academic versus industry research. The experiences with the development of neutralizing anti-IL-13 reagents emphasize the need for inclusion of a biomarker assay in the clinical trials that both identifies individuals that actually have aberrant expression of the pathway of interest and allows determining whether the target of interest is neutralized.

Formats:

• Abstract
 | 
• Article
 | 
• PubReader
 | 
• ePub (beta)
 | 
• PDF (797K)